BHCM
NPCE icon

Brevan Howard Capital Management’s Neuropace NPCE Stock Holding History

Brevan Howard Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,185
Closed -$157K – 2375
2025
Q4 		$157K Buy
+10,185
New +$136K ﹤0.01% 1626
2024
Q2 		– Sell
-15,034
Closed -$198K – 1293
2024
Q1 		$198K Buy
+15,034
New +$214K ﹤0.01% 807

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Brevan Howard Capital Management's NPCE Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Neuropace (NPCE) in Q1 2026, closing a stake of 10,185 shares — an estimated $157K sold.

Brevan Howard Capital Management first reported a position in NPCE in Q1 2024 and held it in 2 quarters. The position peaked at $198K in Q1 2024. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Neuropace position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 10,185 Neuropace shares in Q1 2026, an estimated $157K.
  • Brevan Howard Capital Management first reported a position in Neuropace in Q1 2024 and held it in 2 quarters.
  • Brevan Howard Capital Management's Neuropace position peaked at $198K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.